Heron Therapeuti (HRTX)vsEli Lilly and Company (LLY)
HRTX
Heron Therapeuti
$0.32
-4.96%
HEALTHCARE · Cap: $92.90M
LLY
Eli Lilly and Company
$1,184.91
+0.25%
HEALTHCARE · Cap: $1.06T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 52760% more annual revenue ($79.67B vs $150.71M). LLY leads profitability with a 33.5% profit margin vs -20.5%. LLY earns a higher WallStSmart Score of 76/100 (B+).
HRTX
Avoid27
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -338.6% — below average capital efficiency
Revenue declined 10.8%
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : HRTX
HRTX has a balanced fundamental profile.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : HRTX
The primary concerns for HRTX are EPS Growth, Market Cap, Return on Equity. Debt-to-equity of 21.48 is elevated, increasing financial risk.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
HRTX profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
HRTX carries more volatility with a beta of 1.67 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 27/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Heron Therapeuti
HEALTHCARE · BIOTECHNOLOGY · USA
Heron Therapeutics, Inc., a biotechnology company, is dedicated to developing treatments to address unmet medical needs. The company is headquartered in San Diego, California.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?